What if aging could actually be reversed? And why are investors putting money into companies trying to make it happen?
Dr. Karl Pfleger spent a decade at Google after earning his PhD in Computer Science at Stanford. Today, he's an aging biotech investor who has backed around 30 companies working on one of the biggest challenges in medicine: reversing biological aging.
His investment philosophy is unusually specific. He's interested in therapies that repair the molecular damage associated with aging, rather than simply slowing down the aging process.
In this episode of Return on Health, Niko Hems and Miguel Medina speak with Karl about where the aging biotech industry is heading, which scientific breakthroughs could make the biggest difference, and what it would actually take to demonstrate that a therapy reverses aspects of human aging.
We discuss:
→ Why Karl invests in age-reversal therapies rather than interventions that merely slow aging
→ What makes an aging biotech startup worth investing in
→ Senolytics, stem cells, and epigenetic partial reprogramming
→ Why biological age clocks aren't sufficient proof that an intervention works
→ The regulatory challenges facing aging biotech companies
→ Why immune system rejuvenation and thymus regeneration deserve more attention
→ Whether people alive today could live to 150
→ Why Karl thinks rapamycin, GLP-1 drugs, and single-intervention lifespan studies receive too much attention
→ His personal longevity routine, from exercise and nutrition to supplements and sleep medication
→ Why he believes healthcare systematically underestimates the harm of doing nothing
Karl also explains why he thinks aging research remains severely underfunded compared with cancer research, and what needs to change to bring more therapies into clinical practice.
Chapters
00:00 Why invest in reversing aging?
03:44 From Stanford and Google to aging biotech
08:20 What would a world without biological aging look like?
12:28 Can we reverse aging within our lifetimes?
19:20 The ethics of radical life extension
25:03 How Karl evaluates aging biotech investments
31:10 What makes a biotech startup investable?
33:12 The evidence investors want to see
38:08 How do we prove an aging therapy works?
44:03 Aging versus lifestyle-related disease
50:01 The potential of thymus rejuvenation
50:38 Karl's personal longevity routine
56:42 Rapid-fire questions
57:11 The most promising hallmark of aging
58:29 What's overhyped in longevity?
59:45 The experiments Karl would fund
1:03:29 What needs to change in healthcare?
About our guest
Dr. Karl Pfleger is an aging biotech investor, former Google engineer, and Stanford-trained computer scientist. He founded AgingBiotech.info, a resource tracking companies and developments across the aging biotechnology industry.
Learn more: https://agingbiotech.info
About Return on Health
Hosted by Niko Hems and Miguel Medina, Return on Health brings researchers, physicians, entrepreneurs, and critical thinkers together to question assumptions about health, medicine, and longevity.
Subscribe for conversations about the science, business, and future of human health.
#Longevity #AgingResearch #Biotech #AgeReversal #KarlPfleger
